Biotricity, Inc. (NASDAQ:BTCY) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET
Company Participants
Waqaas Al-Siddiq - Founder and CEO
John Ayanoglou - CFO
Conference Call Participants
Michael Donovan - H.C. Wainwright
Operator
Greetings, and welcome to the Biotricity Fiscal Year 2024 Financial Results and Business Update Call.
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Paul Kunst [ph], Investor Relations. Thank you, Paul. You may begin.
Unidentified Company Representative
Thank you, and good afternoon, everyone. As a reminder, Biotricity's fourth quarter and fiscal year 2024 ended on March 31, 2024. So all figures presented for this period reflect that end date.
Earlier today, Biotricity issued its earnings press release for the period, which highlighted financial and operational results. A copy of the press release is available on the Investor Relations section of the Biotricity website, and the full financials have been filed with the SEC on Form 10-K and posted on EDGAR, which you can find at www.sec.gov.
Before beginning the company's formal remarks, I'd like to remind listeners that today's discussion may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. Biotricity does not undertake to update any forward-looking statements except as required.
At this point, I am pleased to turn the call over to Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq. Please go ahead.
Waqaas Al-Siddiq
Thank you, and thank you everybody, for joining us today. Fiscal '24 has been a transformative year for Biotricity, marked by significant advancements and strategic initiatives that have positioned us on a clear path to profitability and positive EBITDA. We have increased revenue, significantly improved margins and reduced EBITDA losses by almost half.
Our commitment to innovation, strategic partnerships and operational efficiency has allowed us to make remarkable progress across multiple fronts. One of our most significant achievements this year has been the expansion of our Cardiac AI Cloud platform. This initiative, powered by strategic partnerships with industry giants such as Amazon AWS and Google's TensorFlow, leverages over 500 billion heartbeats of anonymized data.
Our AI-driven platform is designed to enhance diagnostic accuracy, improve patient outcomes, and increase clinic profitability. As we pursue FDA clearance for our groundbreaking AI clinical model, we are setting new standards in cardiac care, ensuring every patient receives the highest quality of care.